IL33 and neoplasm: In lung adenocarcinoma model, IL-33 can activate NK in a TNF-α-dependent manner through activating the NF-κB signaling pathway, and promoting the proliferation and activation of CD8+ T cells, consequently inhibiting tumor metastasis.